Long-term clinical outcomes of intravascular brachytherapy for multilayer drug-eluting in-stent restenosis
Main finding · MACE (composite of all-cause death, target lesion revascularisation and myocardial infarction)Result — go to the resultHazard ratio 0.73 95% CI 0.53–0.99Authors' conclusion
Multilayer DES-ISR is associated with a high rate of adverse outcomes at 3-year follow-up. Treatment with IVBT was associated with a lower rate of MACE compared to treatment with a non-IVBT strategy at long-term follow-up.
Study context
- Population
- Patients treated for multilayer DES-ISR (≥2 layers) at Mount Sinai Hospital (2012–2019)mean age 66.6±9.9 years, 25.5% female
- Participants
- 647 patients
- Exposure
- Intravascular brachytherapy (IVBT) vs non-IVBT strategy for multilayer DES-ISR
- IVBTn = 453
- non-IVBTn = 194reference
- Outcome
- MACE:
- All-cause death
- Target lesion revascularisation
- Myocardial infarction
- Follow-up
- 3-year follow-up
Methodological detailspropensity score-adjusted analysis, single-centre (Mount Sinai Hospital)
- Propensity score-adjusted analysis
- Single-centre (Mount Sinai Hospital)
Main finding
As reported in the abstract
Hazard ratio
0.73
95% CI 0.53–0.99
P = 0.044
By group
IVBTvs non-IVBT
hazard ratio 0.73 (95% CI 0.53–0.99); P = 0.044
Observational data: associations, not effects.
Further findings
Received a DES · significantly less likely in IVBT group
P < 0.001
Mean
| Outcome | IVBT | non-IVBT | P value |
|---|---|---|---|
| Mean SYNTAX scoreLower in IVBT group | 11.9 (SD 10.7) | 14.2 (SD 11.3) | P = 0.028 |
Individual components of major adverse cardiac events (MACE) · 3-year follow-up
- No significant differences between groups
Original publication
Long-term clinical outcomes of intravascular brachytherapy for multilayer drug-eluting in-stent restenosis. EuroIntervention. Published 7 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →